Home > Back to Publisher > Report Information

Molecular Diagnostics

Global Industry Analysts
October 1, 2010
659 Pages - SKU: GJOB2876539

Abstract Table of Contents Related Reports

Countries covered: Global

This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biomérieux, CytoCore Inc., ELITech Group, GE Healthcare, Gen-Probe Inc., Genzyme Corporation, Genzyme Genetics, MiraiBio, Inc., Novartis Vaccines & Diagnostics, Inc., QIAGEN N. V, Quest Diagnostics, Inc., Roche Diagnostics, Siemens Healthcare Diagnostics, and Tecan Group Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Data Interpretation & Reporting Level; Product Definitions and Scope of Study
2. INDUSTRY OVERVIEW: Global Market Outlook
3. A REVIEW OF MEDICAL DIAGNOSTICS MARKET: Clinical Diagnostics Industry - Trends and Tendencies; Diagnostic Tests - Classification; Nucleic Acid Diagnostics Market - An Overview; Molecular Diagnostics - Growth Drivers; Molecular Diagnostics - A Replacement and Enabling Technology; Molecular Diagnostics for Lymphoid Malignancies
4. COMPETITIVE DYNAMICS IN THE MOLECULAR DIAGNOSTICS MARKET: Key Players and Their Technologies
5. MARKET TRENDS & ISSUES: Market Consolidations on the Way to Integrate in Vivo and in Vitro Diagnostics; Global Molecular Diagnostics on High Growth Curve; Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market; Towards Tailoring the Right Treatment for the Right Disease; Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes; Molecular Diagnostics and Intellectual Property; Business Opportunities in the Offing; Challenges Facing the Molecular Diagnostic Market; Medical Training and Practice Challenges; Shortcomings to Overcome; Limited Reimbursements by Third Party Payers - A Stumbling Block; Hurdles All the Way for Companies Eyeing Molecular Diagnostics; Product Marketing - Key to Commercial Success; Integration of Molecular Diagnostics into Therapeutics; Molecular Diagnostics - Moving from Centralization to Decentralization; Migrating to Decentralized Format; Going Ahead with Decentralization
6. PRODUCT & TECHNOLOGY OVERVIEW: Molecular Diagnostics - Definition & Scope; Molecular Diagnostics - Impact on Healthcare; Utility of Molecular Diagnostic Tests; Background of Molecular Diagnostics; Unabated Developments in Molecular Diagnostics Technology; DNA Probe Based Products; RNA Diagnostics; Complementary Molecular Diagnostic Technologies; Technologies on the Anvil
7. AN INSIGHT INTO APPLICATIONS OF MOLECULAR DIAGNOSTICS: Infectious Diseases Testing; Genetic Disease Testing Applications; Cancer Screening & Diagnosis; Other Testing Applications
8. PRODUCT DEVELOPMENTS/ INTRODUCTIONS: Life Technologies Unveils ViralSEQTM Vesivirus Detection Kit; Applied Biosystems New Forensic DNA Kits; Quest Diagnostics Launches ColoVantage™ Test; QIAGEN Introduces CE-labeled KRAS Kit; Roche Introduces Cobas 4800; bioMérieux Launches Upgraded Version of NucliSENS EasyQ® Influenza A/B Test; bioMérieux Introduces NucliSENS EasyQ® MRSA; Roche Launches AMPLILINK 3.3 Series Software and cobas p 630 Instrument; Applied Biosystems Unveils 3500 Series and 3500 DX Series Genetic Analyzer; Prometheus Laboratories Introduces New Range of Cancer Diagnostic Products; Sequenom Introduces SensiGene Cystic Fibrosis Carrier Screening Test; Triplex and MedMira to Unveil New Rapid Tests; Applied Biosystems to Introduce New Range of TaqMan® PCR Assays; Quest Diagnostics Unveils HIV-1 Coreceptor Tropism Test; Luminex introduced New Range of Cystic Fibrosis Tests; bioMérieux Introduces VIDAS® EBV Test; Luminex Unveils Two Novel Cystic Fibrosis Tests; MEDomics Launches MitoDx™ for Diagnosing Mitochondrial Diseases; Exagen Diagnostics Unveils eXaIBStest and eXaIBD Blood Tests; bioMérieux Introduces NucliSENS EasyQ® HIV-1 v2.0 Test; PreAnalytiX Introduces PAXgene® Blood miRNA Kit; ViraCor Laboratories Introduces New JCV Test; ViraCor Laboratories Rolls Out JC Virus Detection Test; Focus Diagnostics Laboratory Introduces PCR Test; Siemens Launches CLINITEK AUWi Urine Analyzing System; Ocimum Biosolutions to Introduce New H1N1 Virus Detection Test; Myriad Genetics Introduces OnDose for Cancer Diagnosis; Applied Biosystems Introduces TaqMan® Array Gene Signature Plates; GeneNews to Develop Blood-Based Diagnostic Tests; Seegene Rolls Out Seeplex® Diarrhea ACE Detection Test; Seegene Unveils Seeplex® Meningitis ACE Detection test; Cepheid Introduces Xpert MRSA/SA Nasal Diagnostic Test; Roche to Launch LightCycler Test; Xenomics Unveils New Technology for Analyzing In Vivo Cell Death; bioMerieux Unveils NucliSENS EasyQ® HPV Molecular Analytical Test; Xenomics to Introduce Innovative Gender Prediction Test; Evogen Unveils New EvoCyclerTM HD12 Molecular Diagnostics System; Siemens Healthcare Launches Innovance Antithrombin Test; Rosetta Genomics Launches miRview™ meso Diagnostic Test; ViraCor Laboratories Introduces Cytomegalovirus Antiviral Resistance Test; Abbott Launches Diagnostic Test for HPV Detection; Pathwork Diagnostics Introduces Tissue of Origin Test; Evogen to Offer Diagnostic Tests; Axial Unveils a Test for Detecting AIS; Myriad Introduces Prezeon; Exiqon Launches Test for Colon Cancer; Siemens Launches Diagnostic Tests for Testing Viral Load; QIAGEN Launches a Molecular Test for Testing the K-ras Gene; Spartan Launches DX-12 DNA Analyzer; ViraCor Introduces an Assay for Fungal Infections; Illumina Introduces mRNA-Seq; QIAGEN Rolls Out a New Diagnostic Test for AIDS; QIAGEN Introduces miScript miRNA Inhibitors® and miScript miRNA Mimics® Test Technologies; QIAGEN Introduces New Kits for Gene Expression and Function Analysis; QIAGEN Introduces New Products in EpiTect Product Line; QIAGEN Launches QIAsymphony® Novel Modular Platform; Q Chip Introduces ReaX™ PCR Beads; ViraCor Rolls Out a New Test for Detecting Enterovirus; TMD Rolls Out New Tests for Colorectal Cancer; Gen-Probe Unveils APTIMAR® HPV Tests in Europe; Genzyme Genetics Introduces KRAS Mutation Analysis; China Medical Develops a Test for Prostate Cancer; Palex Medical to Introduce SoftPAP™
9. PRODUCT INTRODUCTIONS IN THE RECENT PAST - A PERSPECTIVE BUILDER: TMD Launches Test for K-ras Mutations in Colorectal Cancer Patients; CombiMatrix Releases Updated Version of Constitutional Genetic Array Test; Myriad Introduces TheraGuide 5-FU; CMDX Unveils First HemeScan™ Prognostic; CombiMatrix Introduces HemeScan™ MDS; Genzyme Rolls Out Two New Molecular Tests; Dade Behring Launches The Quadriga BeFree; BD Diagnostics Introduces The BD Viper System; Genzyme Introduces P53 Mutation Analysis; CombiMatrix Molecular Diagnostics Rolls Out A New Melanoma Test; Qiagen Launches Fast Cycling PCR Product Line; Genzyme Releases Molecular Assay for Colorectal Cancer Patients; Roche Diagnostics Launches LightCycler 480 System; Roche Diagnostics Introduces AmpliChip CYP450 Test; SEQUENOM Unveils iPLEX™; SEQUENOM Develops a Novel Process; Cerner Corp Develops Cerner Millennium(R) PathNet Helix (TM); Roche Diagnostics Launches Amplicor HPV Test; Gen-Probe Launches Procleix Ultrio Assay in Europe; Gen-Probe Launches TIGRIS®DTS™ System; BD Biosciences Introduces BD QZyme™ Assay; Epoch Biosciences Releases MGB Eclipse™; QIAGEN Unveils BioRobot MDx DSP Device; Digene Unveils DNAwithPap; Exact Sciences Launches Non-Invasive Test for Colorectal Cancer; TDT Introduces GCC-B1 Blood Test to Detect Colorectal Cancer; AcroMetrix Joins Hands with Nabi to Introduce ViroSure; Orchid Cellmark Introduces DNA Express Service; Roche Develops New IVD Real-Time PCR Instrument; Nanogen Rolls Out First Ever ASR; Digene Introduces Hybrid Capture; Digene’s Hybrid Capture 2 HPV DNA Test to Effectively Identify Cervical Cancer; PGD to Eliminate Human Eggs Affected with Alzheimer's Disease; Esoterix Introduces New HCV Testing Program; Gen-Probe Releases New APTIMA Combo 2 Assay; Nycomed’s NeoSpect to Identify Suspected Lung Cancer; DNAPrint Introduces New Services to Assist Forensic Market; IMBG Develops an Efficient Procedure to Treat Diseases
10. RECENT INDUSTRY ACTIVITY: Life Technologies Obtains IVD Marking for 7500 Fast Dx PCR Instrument; Xenomics Changes Name to TrovaGene; Abbott and GSK Team Up in the Area of Molecular Diagnosis; Asuragen Enters Into Collaborations for Pancreatic Cancer Tests; Transgenomic Licenses Intellectual Property from Integragen; Health Discovery Inks Agreement with Pancreas, Biliary and Liver Surgery Center of New York; Qiagen Enters into Agreement with Celera; The Tecan Group Inks Agreement with Enigma; AdnaGen AG and TATAA Molecular Diagnostics Inks Agreement; Northeast Pharmaceuticals to Establish Biopharma JV with Shenyang; Wescor Divests Microarray Technology Related Assets to Gamida For Life Group; Predictive Biosciences Takes Over OncoDiagnostic Laboratory; Applied Biosystems Obtains Approval for AmpFℓSTR® MiniFiler™ PCR Amplification Kit; Life Technologies Acquires AcroMetrix; Ipsogen SA and The Institut Curie Enters into Scientific Collaboration Agreement; bioTheranostics and Ferrer inCode Enters into Commercial Agreement; Quidel Corp Signs Definitive Agreement to Purchase Diagnostic Hybrids; Abbott Obtains CE Marking for New Diagnostic Test; Transgenomic Enters into Licensing Agreement with Gene Solutions; QIAGEN Acquires SABiosciences; Corgenix Medical and BG Medicine Inks Supply Agreement; Roche receives FDA Approval for Additional Usage of cobas® TaqScreen MPX Test; Gen-Probe Obtains FDA Approval for Marketing of ProParaflu+TM Assay; bioMerieux Enters into Agreement with GSK; Tecan Group and Hologic Sign Agreement; QIAGEN Takes Over DxS; Tyrian Ends Partnership with Becton, Dickinson and Co; Becton, Dickinson and Co to Purchase HandyLab; Quidel and BioHelix Enter into Agreement; Gen-Probe to Take Over Prodesse; Summit Partners Acquires Stake in ApoCell; Merck to form Alliance with QIAGEN; Gen-Probe to Spin Off Industrial Testing Assets; ImClone Systems and Bristol-Myers Squibb Enter into Collaboration with DxS; Danaher to Acquire A Joint Venture Company; Abbott Enters into Alliance with Pfizer for Molecular Diagnostic Test; Rosetta and Warnex Ink Distribution Agreement; ViraCor Laboratories Merges with IBT Laboratories; ELITech Takes Over Assets of Nanogen; LabCorp Signs Definitive Agreement with Monogram Biosciences; Axial Biotech and University of Utah Enter into Collaboration; Celera and Bayer Schering Pharma Sign Licensing Agreement; AVESTHAGEN Enters into Collaboration with VTT Technical Research Centre; 3M Terminates Collaboration Agreement with Gen-Probe; BioGenex and Abbott Expand Joint Development and Distribution Agreement; Pfizer Extends Collaboration Agreement with Monogram Biosciences; BD Diagnostics Inks Agreement with HandyLab; TriLink BioTechnologies and Osmetech Molecular Diagnostics Ink Agreement; PerkinElmer Buys Analytica of Branford; Ipsogen Signs Agreement with Arup Laboratories; Prometheus Laboratories and Rosetta Genomics Ink Agreement; AMDL and Precision Diagnostic Laboratory Signs Agreement; Osmetech Signs Agreement with Fisher HealthCare; Interleukin Genetics Inks Licensing Agreement with LABEC Pharma; deCODE Genetics Inks Licensing Agreements with Celera; Nuvera Biosciences Signs Licensing Agreement with Veridex; GE Healthcare Inks Research Agreement with Brigham and Women's Hospital; Gen-Probe Purchases Tepnel Life Sciences; AdnaGen AG Receives US Patent; Agilent Technologies Selects Asuragen as Certified Service Provider; Genstruct Enters into Partnership with Gene Logic; Lab21 Takes Over Biotec Laboratories; ProGenTech and Innovative Biosensors Jointly Sign Extension Agreement; Nanogen Signs and Scandinavian Gene Synthesis Inks Agreement; Health Discovery Corporation Inks Licensing Agreement with Abbott; BD Diagnostics Receives CE Marking for Amplified DNA Assays; Transgenomic Signs Licensing Agreement Power3 Medical Products; Rubicon Genomics and Abbott Enter into Licensing Agreement; Novartis Extends Collaboration with Gen-Probe; Eurogentec Receives ISO-Certification for IVD Oligonucleotides; Dako and OSI Pharmaceuticals Enter into Collaboration; Combimatrix Molecular Diagnostics and Lenetix Enter into Partnership; Sequenom to Acquire AttoSense™ Tests of SensiGen; Epigenomics AG and Sysmex Ink Research and Development Collaboration Deal; Gene Express and Biogenuix Medsystems Signs Distribution Agreement; Gene Express and Funakoshi Enter into Distribution Agreement; BD and Company Obtains FDA Approval for Marketing GeneOhm™ Cdiff Test; XDx and Bristol-Myers Squibb Company Signs Collaborative Agreement; Rosetta Genomics and Teva Pharmaceutical Industries Signs Distribution Agreement; ProGenTech Inks Deal with Center for Disease Control and Prevention in China; National Jewish Health Signs Agreement with Laboratory Corporation of America Holdings; DxS and Amgen Ink Agreement; Enigma Diagnostics Inks Term Sheet with Roche Molecular Systems; Quintiles Transnational Purchases Targeted Molecular Diagnostics; Invitrogen Merges with Applied Biosystems; Gen-Probe Receives CE-Mark for APTIMA® HPV Test; BD Receives Health Canada Licensing for BD GeneOhm™ Cdiff Molecular Assay; Abbott Molecular and Epigenomics Amend Licensing Agreement; Nanogen Inks Agreement with A. Menarini Diagnostics; EraGen Biosciences Signs Distribution Agreement with Inter Medico; Spartan Bioscience Enters into Agreement with NorDiag; Celera and Nanogen Extend License Agreement; NorDiag and Molzym Enter Into Collaboration and Distribution Agreements; ZyGEM Inks Agreement with Advalytix Products; Response Genetics and NeoGenomics Laboratories Enter into Agreement; SIRS-Lab Obtains Certification for Quality Management of In-Vitro Diagnostics; China Medical and Molecular Diagnostics Technologies Ink Agreement; QIAGEN Takes Over Entire Assets of Biosystems Division of Biotage; Cepheid Secures FDA Approval for Xpert™ Test; Osmetech Signs Agreement with Qiagen; Luminex Enters into Agreement with BD Diagnostics; bioMérieux Acquires AviaraDx; Pall Takes Over GeneSystems; Corgenix Medical and BG Medicine Ink Agreement; Diatherix Laboratories Receives CLIA Certificate; Novartis Diagnostics Secures FDA Authorization for PROCLEIX® ULTRIO® Assay; Bio-Reference Laboratories to Start K-ras Mutation Testing; Hologic Purchases Third Wave Technologies; Asuragen and Affymetrix Ink an Agreement; Health Discovery and DCL Medical Laboratories Sign an Agreement; Osmetech Receives the US Food and Drug Administration Clearance; BD Diagnostics Secures CE Marking for BD GeneOhmTM Cdiff molecular Test; Siemens Healthcare Diagnostics Secures CE-Marking Approval; QIAGEN Takes Over Corbett Life Science; QIAGEN Obtains CE Mark Approval for Borrelia and HIV PCR Kits; Gen-Probe Receives License from Xceed Molecular; Nanogen Bags Contract from US Centers for Disease Control and Prevention; Gen-Probe to Take Over Innogenetics; Third Wave Technologies to Buy Intellectual Property; Prodesse and Quidel Sign an Agreement; Siemens Healthcare Diagnostics Licenses Certain Testing Rights; bioMérieux Signs MoU with Foundation for Innovative New Diagnostics; QIAGEN Collaborates with GENEART; Agilent Technologies and Agendia to Enter into Partnership; Siemens Inks Non-Exclusive Deal with Laboratory Corporation of America® Holdings; BD Diagnostics Receives CE-Marking for BD GeneOhm™ VanR Test; Health Discovery Completes Trials on Molecular Diagnostic Test on Prostate Cancer; Gen-Probe and Agreement DiagnoCure Amends; License Agreement; OccuLogix Purchases Remaining Stake in OcuSense; Thermo Fisher Scientific Signs Agreement with Nanogen; DCL Medical Laboratories and Third Wave Technologies Enter into Partnership; Gen-Probe Commences Clinical Trial of APTIMA® Assay; Immucor to Buy BioArray Solutions; Epigenomics Partners with Abbott Molecular; Hitachi High-Technologies and bioMerieux Enter into Partnership; Luminex Molecular Diagnostics Signs Agreement with Abbott; Abbott Signs Agreement with OSI Pharmaceuticals, Roche and Genentech; Exiqon Takes Over Oncotech; Siemens Secures FDA Authorization for VERSANT™; Molecular System; Vermillion, Johns Hopkins Ink Agreements to Develop Molecular Diagnostic Tests; Beckman Coulter Inks Licensing Agreements with National University of Ireland
11. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER: Roche Takes over BioVeris; Siemens Acquires Dade Behring; DiagnoCure Acquires Catalyst Oncology; Burrill & Co Takes over Expression Diagnostics; Solis Acquires Bertrand; ParagonDx LLC Acquires Gentris Diagnostics; Beckman Collaborates to Discover CVD Symptoms; Exiqon to Take over Oncotech; Roche to Acquire Ventana; Qiagen Merges with Digene; Qiagen & Bio One Capital Collaborates; AGT & MAL Signs MoU; Qiagen Obtains Licenses to Real-Time PCR; Cepheid Acquires Sangtec; Source MDx Collaborates with Pfizer; Nanosphere Receives FDA Clearance for Second Molecular Diagnostic Test; QIAGEN Acquires eGene; Quest Diagnostics Acquires AmeriPath; Mayo and ILMN Team up to Develop Molecular Diagnostics for Complex Diseases; CHEO and ILMN Team up to Develop Molecular Diagnostics for Newborn Screening; Siemens Medical Solutions USA Sets Up Siemens Medical Solutions Diagnostics; Novartis Acquires Chiron; Quest Diagnostics Acquires Focus Diagnostics; Becton Dickinson Acquires GeneOhm; Iris International Acquires Leucadia Technologies; Predicant Biosciences Acquires Pathwork Informatics; AmeriPath Acquires Rose Pathology Associates; Nanogen Acquires Amplimedical’s Diagnostics Division; Nanogen Acquires Immunoassay Test Business of Spectral Diagnostics; Fisher Scientific Acquires Athena; Qiagen Acquires Genaco; Bio-Rad Acquires Blackhawk BioSystems; IRIS International Acquires Leucadia Technologies; Qiagen Acquires Shenzhen PG Biotech; Qiagen Acquires Artus GmbH; Nanogen and Fisher Increases Agreement Tenure; Qiagen Signs An Agreement with Gentra; Qiagen Inks an Agreement with VLA; Stratagene Signs an Agreement with AROS; Bayer Inks an Agreement with Hamilton Company; Prodesse and Invitrogen Sign a Pact; Illumina Forms Collaboration with ReaMetrix; PerkinElmer Signs an Agreement with Jacobi Medical; UniPath and Roche Diagnostics Sign an Accord; Qiagen Alliances with Eppendorf; Olympus and Cangen Extends their Research Collaboration; Toppan, Shimadzu and Third Wave Collaborate to Develop A POC Molecular Diagnostic Instrument; Focus Diagnostics Signs an Agreement with Stratagene; Innogenetics Inks an Agreement with Roche Diagnostics; The University of Goettingen, Bruker Daltonik and PANATecs Collaborate to Develop New Molecular Diagnostic Assays for Rheumatoid Arthritis; Focus Diagnostics Enters into an Agreement with Luminex; QIAGEN Expands Strategic Alliance with Protedyne; Specialty Laboratories Teams Up with SEQUENOM and Siemens; Gen-Probe Enters into a Licensing Agreement with Corixa; Gen-Probe Inks a Supply and Purchase Agreement with F. Hoffmann-La Roche; Gen-Probe Enters into a Licensing Agreement with AdnaGen; Roche Establishes New Polymerase Chain Reaction (PCR) Manufacturing Center; Ambion Establishes a Subsidiary in Japan; Gen-Probe Gains FDA Approval for APTIMA®; Blood Center of Southeastern Wisconsin Adopts Ambion’s Signature™ CF 2.0 ASR; Orchid Biosciences, Inc. Becomes Orchid Cellmark Inc; Roche Acquires IGEN International; GE Takes Over Amersham Plc; Nanogen Acquires SYN•X PHARMA; Nanogen Merges with Epoch Biosciences; Sequenom Enters into Collaboration with Siemens; TMD Joins Hands with University of Texas; GE Global and Two other Companies Enters into a Joint Research Collaboration; Third Wave and BML Extend Partnership to Promote Molecular Diagnostic Tests; ViroLogic Signs an Agreement with ACLARA; Abbott and BioGenex Sign an Agreement; Novation Signs a Pact with Bayer Diagnostics; Osmetech Enters into a Licensing Agreement with LGC Limited; Licensing Agreement between DxS Ltd and Sangtec Molecular Diagnostics; EraGen Biosciences Strikes a Deal with Inter Medico; Nanogen Bags Patent for Molecular Diagnostics and Optical Waveguides Systems; Gen-Probe Secures Regulatory Approval for PROCLEIX ® ULTRIO™ Assay; Gen-Probe Bags FDA Approval to Use TIGRIS DTS System for STD Testing; Gen-Probe Acquires Majority Stake in MLT; AmeriPath in Strategic Alliance with Roche; Abbott and Promega to Offer Nucleic Acid Extraction Products; Ambion RNA to Offer Services Through BBI; STMicroelectronics Inks an Agreement with Mobidiag; BBI Contracts with IDS; Focus to Assist FDA in Evaluation of Antimicrobial Resistance; Bayer Acquires Rights to Detect HCV and HIV Antibodies; Cenetron in Strategic Alliance with Roche; Saint Luke's Health System in Alliance with Roche; US LABS Adds Gene Expression Profiling Capabilities on (FFPE) Tissue; Bayer Acquires Visible Genetics; Qiagen Enters into an Agreement with RMS; Dabur Starts a New Molecular Diagnostic Lab; Roche Gains Rights for Cervical-Cancer Testing Market; Ventana Acquires License From MDI; Genzyme Genetics Gains Rights for Genzyme Molecular’s Cancer Diagnostics; Abbott in Strategic Alliance with Celera; MDI and DiagnoCure Join Hands to Integrate ImmunoCyt/uCyt with InPath; MDI and PMI to Jointly Promote Lung Cancer Detection System; MDI in Agreement with Esoterix; MDI to Expand Product Base in China; Abbott and Tecan to Offer Devices for Molecular Diagnostic Assays; Invirion Extends Licensing Agreement with MDI; Ambion RNA Grants License to Celera; Morewood and IT&M to Introduce New Micro Array System; Ambion RNA Constructs New Manufacturing Facility; LabCorp Teams up with Celera; Athena Launches New DNA Testing for TSC; Genezyme Genetics Expands Cancer Testing Services; Promega Teams Up with Abbott; ChromaVision and Ventana Join Hands to Market Testing Process that Identifies HPV; OraSure in Agreement with Abbott; Nanogen and Bionomics to Jointly Develop IVD for Epilepsy; DiagnoCure and Compugen Join Hands to Develop Tests to Identify Epithelial Cancers; OraSure Gets FDA Approval for OraQuick Rapid HIV-1 Test; Ampersand and Accumed Merged to Form MDI; Abbott Acquires Vysis; Millennium and Abbott Forge 5-Year Drug Deal; Bode Enters into Agreement to Undertake DNA Testing; BD Contracts with TriPath to Develop Molecular Diagnostics; TriPath Installs New Interactive System; Archemix in Strategic Alliance with RPI; AmeriPath Strengthens Relationship with Genomics Collaborative
12. FOCUS ON SELECT GLOBAL PLAYERS: Abbott Laboratories (US); Applera Corp. (US); Biomérieux (France); CytoCore Inc. (US); ELITech Group (France); GE Healthcare (US); Gen-Probe, Inc. (US); Genzyme Corp. (US); MiraiBio, Inc. (US); Novartis Vaccines & Diagnostics, Inc. (US); QIAGEN N.V (The Netherlands); Quest Diagnostics, Inc. (USA); Roche Diagnostics (Switzerland); Siemens Healthcare Diagnostics (US); Tecan Group Ltd. (Switzerland)
13. GLOBAL MARKET PERSPECTIVE: Table 6: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart); Table 7: World Historic Review for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart); Table 8: World 11-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart); Table 9: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart); Table 10: World Historic Review for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart); Table 11: World 11-Year Perspective for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart); Table 12: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart); Table 13: World Historic Review for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart); Table 14: World 11-Year Perspective for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart); Table 15: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Cancer Screening) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart); Table 16: World Historic Review for Molecular Diagnostics (Cancer Screening) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart); Table 17: World 11-Year Perspective for Molecular Diagnostics (Cancer Screening) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
14. UNITED STATES: A. Market Analysis; B. Market Analytics
15. CANADA: Market Analysis
16. JAPAN: Market Analysis
17. EUROPE: A. Market Analysis; B. Market Analytics
17a. FRANCE: Market Analysis
17b. GERMANY: Market Analysis
17c. ITALY: Market Analysis
17d. UNITED KINGDOM: Market Analysis
17e. REST OF EUROPE: Market Analysis
18. ASIA-PACIFIC: A. Market Analysis; B. Market Analytics
19. REST OF WORLD: Market Analysis
Competition: Total Companies Profiled: 101 (including Divisions/Subsidiaries - 121) Region/Country Players; The United States 88; Canada 5; Europe; Asia-Pacific (Excluding Japan) 2

More Global Molecular Diagnostics Reports

In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers & Microbiology Culture) – Global Trends & Forecasts to 2016 by MarketsandMarkets
The global in-vitro diagnostics (IVD) market was valued at $44 billion in 2011 and is expected to have a modest growth during the study period. ...

2012 World Molecular Diagnostics Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the molecular diagnostics market, including estimates of facilities performing DNA sequencing and molecular diagnostic testing, as well as ...

2012 Global Molecular Diagnostics Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant ...

The 2012 Global Molecular Diagnostics Market: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the molecular diagnostics market, including estimates of facilities performing DNA sequencing and molecular diagnostic testing, as well as ...

Genetic Testing by Global Industry Analysts
This report analyzes the worldwide markets for Genetic Testing in US$ Million. The US market is analyzed by the following Segments: Prenatal and Newborn Genetic ...

See all reports like this >>

Molecular Diagnostics

Share this report

Other tasks

Research Assistance

Related Markets

Molecular Diagnostics Reports

Free Alert Me service